Filing Flows › Prelude Therapeutics (PRLD) › Next earnings date
Prelude Therapeutics (PRLD) earnings on Nov 11, 2026: what to expect
Prelude Therapeutics (PRLD) is expected to report earnings on Nov 11, 2026 (estimated), in 3 days, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.14 (−$0.16 to −$0.13, 3 estimates) on revenue of $29.0M, against −$0.26 and $6.5M a year ago. It beat the EPS estimate in 75% of the quarters on record; Filing Flows' model gives it a 76% chance of beating next time.
The last report
Prelude Therapeutics reported revenue of $5.7M for the second quarter 2026, net loss $13.9M. How it makes money → · Every quarter →
Prelude Therapeutics' latest quarter
Prelude Therapeutics, Q2 2026: revenue $5.7M, operating margin -270.9%, net loss $13.9M, operating cash flow −$15.6M. The chart follows the revenue to costs, profit and cash.
Questions
When does PRLD report earnings?
Prelude Therapeutics is expected to report on Nov 11, 2026 (estimated).
What are analysts expecting from Prelude Therapeutics?
EPS of −$0.14 and revenue of $29.0M for the quarter.
Does Prelude Therapeutics usually beat earnings?
It beat the consensus EPS estimate in 75% of the quarters on record.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.